INSMED Inc 8-K

What Happened

• On April 7, 2026 Insmed Incorporated (INSM) announced topline efficacy and safety results from its Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) and said it will discontinue development of brensocatib for HS. The announcement was made via press release and reported in an 8-K filing.
• The randomized, double‑blind, placebo‑controlled CEDAR study enrolled 214 adults at 72 global sites. Patients were randomized 1:1:1 to brensocatib 10 mg, brensocatib 40 mg, or placebo once daily for 16 weeks.

Key Details

• Primary endpoint (percent change from baseline in total abscess and inflammatory nodule [AN] count at Week 16): brensocatib 10 mg = 45.5% reduction; brensocatib 40 mg = 40.3% reduction; placebo = 57.1% reduction.
• Safety during the 16‑week placebo‑controlled period (N per arm): 10 mg (N=74) any TEAE 41 (55.4%), severe TEAE 1 (1.4%), serious TEAE 3 (4.1%); 40 mg (N=70) any TEAE 30 (42.9%), severe TEAE 0, serious TEAE 1 (1.4%); placebo (N=70) any TEAE 32 (45.7%), severe TEAE 0, serious TEAE 1 (1.4%).
• After 16 weeks, participants either continued blinded brensocatib or placebo patients were re-randomized to brensocatib 10 mg or 40 mg.
• Insmed intends to present these CEDAR data at a future medical congress.

Why It Matters

• For investors, the most material facts are that the CEDAR study did not show improved AN count reductions versus placebo at Week 16 and Insmed is discontinuing the HS development program for brensocatib. This directly affects the potential market opportunity and value of that asset within Insmed’s pipeline.
• The company disclosed the results and program discontinuation publicly (8-K), and said it will present full data later; any future updates or reallocation of resources may be reported in subsequent filings.